At this week's Allicense 2015 meeting in San Francisco, Jon Norris, managing director of the health care practice at Silicon Valley Bank, described the current biotech financing environment as "a frothy market, but a healthy frothy market."

Juno Therapeutics Inc. looked down the West Coast to expand the potential of its genetically engineered T-cell product pipeline, handing a partnership with a small up front but considerable potential to Fate Therapeutics Inc., of San Diego.

Launched in 2012, Symbiomix Therapeutics LLC sped quickly from baby steps to a full sprint in advancing its single asset, SYM-1219, for the treatment of bacterial vaginosis (BV).

Shares of Spark Therapeutics Inc. tumbled Monday morning after a paper published in The New England Journal of Medicine suggested that a gene therapy approach to treating Leber congenital amaurosis (LCA) peaked one to three years after treatment, followed by a decline.

First quarter sales in the bellwether diabetes franchise at Sanofi SA dropped 3.2 percent, to €1.837 billion (US$2.054 billion), the Paris-based pharma reported early Thursday.

In the heady days when venture capital (VC) was flowing like a waterfall, not-for-profit support of biotech endeavors was considered – by both parties – as a type of gravy, sometimes with the end goal of producing a scientific paper but rarely with a clinical milestone in mind.

Here we go again. Biotech stocks led Monday's market selloff, with the Nasdaq Biotech Index falling 4.1 percent following disappointing news from a pair of companies. Amgen Inc. led the stampede after FDA briefing documents posted Monday suggested its cancer immunotherapy drug, talimogene laherparepvec (T-vec), will face strong headwinds at Wednesday's joint meeting of the Cellular, Tissue and Gene Therapies and Oncologic Drugs Advisory Committee.

The critical tone of FDA briefing documents examining Amgen Inc.'s cancer immunotherapy drug, talimogene laherparepvec, or T-vec, in advance of Wednesday's joint meeting of the Cellular, Tissue and Gene Therapies and Oncologic Drugs Advisory Committee (adcom) wasn't especially surprising, given that T-vec showed a "strong trend" but missed statistical significance in overall survival (OS) in a phase III study in metastatic melanoma.

Covering the American Academy of Neurology's (AAN) 67th annual meeting in Washington – a gathering of nearly 13,000 clinicians, researchers, students, industry reps and even a few patients – was an exercise in exhaustion and a labor of love. I have a vested interest in this space, having lost my mother to glioblastoma before I reached my teens and my mother-in-law, just months ago, to Alzheimer’s disease. An even more compelling interest is the well-being of my husband, who was diagnosed with epilepsy at age 15, a year after a head injury during a soccer game. At age 40, he...

WASHINGTON – Among the hundreds of posters and presentations at the American Academy of Neurology (AAN) 67th annual meeting that addressed various aspects of Alzheimer's disease (AD), a little bit of data from Biogen Inc. generated a disproportionate amount of chatter.